The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria
Open accessAbstract
BACKGROUND: Paroxysmal nocturnal hemoglobinuria (PNH) arises from a somatic mutation of the PIG-A gene in a hematopoietic stem cell and the subsequent production of blood cells with a deficiency of surface proteins that protect the cells against attack by the complement system. We tested the clinical efficacy of eculizumab, a humanized antibody that inhibits the activation of terminal complement components, in patients with PNH. METHODS: Eleven transfusion-dependent patients with PNH received infusions of eculizumab (600 mg) every week for four weeks, followed one week later by a 900-mg dose and then by 900 mg every other week through week 12. Clinical and biochemical indicators of hemolysis were measured throughout the trial. RESULTS: Mean lactate dehydrogenase levels decreased from 3111 IU per liter before treatment to 594 IU per liter during treatment (P=0.002). The mean percentage of PNH type III erythrocytes increased from 36.7 percent of the total erythrocyte population to 59.2 percent (P=0.005). The mean and median transfusion rates decreased from 2.1 and 1.8 units per patient per month to 0.6 and 0.0 units per patient per month, respectively (P=0.003 for the comparison of the median rates). Episodes of hemoglobinuria were reduced by 96 percent (P<0.001), and measurements of the quality of life improved significantly. CONCLUSIONS: Eculizumab is safe and well tolerated in patients with PNH. This antibody against terminal complement protein C5 reduces intravascular hemolysis, hemoglobinuria, and the need for transfusion, with an associated improvement in the quality of life in patients with PNH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hematology: Basic Principles and Practice
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-3-238_2 · Cited by 1,857
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Takeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., Takahashi, M., Kitani, T., & Kinoshita, T. (1993) · Cell · doi:10.1016/0092-8674(93)90250-t · Cited by 1,029
Natural History of Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P., Lewis, S. M., Bessler, M., Luzzatto, L., & Dacie, J. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511093331904 · Cited by 907
Self-citationRollins, S. A., & Sims, P. J. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.9.3478 · Cited by 405
Self-citationHolguin, M. H., Fredrick, L. R., Bernshaw, N. J., Wilcox, L. A., & Parker, C. J. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114172 · Cited by 403
Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene.
Bessler, M., Mason, P. J., Hillmen, P., Miyata, T., Yamada, N., Takeda, J., Luzzatto, L., & Kinoshita, T. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06240.x · Cited by 389
Self-citationInhibition of complement activity by humanized anti-C5 antibody and single-chain Fv
Thomas, T. C., Rollins, S. A., Rother, R. P., Giannoni, M. A., Hartman, S. L., Elliott, E. A., Nye, S. H., Matis, L. A., Squinto, S. P., & Evans, M. J. (1996) · Molecular Immunology · doi:10.1016/s0161-5890(96)00078-8 · Cited by 363
Self-citationA clinical safety trial of stroma‐free hemoglobin
Savitsky, J. P., Doczi, J., Black, J., & Arnold, J. D. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197823173 · Cited by 359
Yamashina, M., Ueda, E., Kinoshita, T., Takami, T., Ojima, A., Ono, H., Tanaka, H., Kondo, N., Orii, T., Okada, N., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010253231707 · Cited by 351
The effects of recombinant human hemoglobin on esophageal motor function in humans
Murray, J. A., Ledlow, A., Launspach, J., Evans, D., Loveday, M., & Conklin, J. L. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90584-7 · Cited by 230
Rinder, C. S., Rinder, H. M., Smith, B. R., Fitch, J. C., Smith, M. J., Tracey, J. B., Matis, L. A., Squinto, S. P., & Rollins, S. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118195 · Cited by 213
Self-citationFujita, T., Inoue, T., Ogawa, K., Iida, K., & Tamura, N. (1987) · The Journal of experimental medicine · doi:10.1084/jem.166.5.1221 · Cited by 204
Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction
Corbin, J. D., Francis, S. H., & Webb, D. J. (2002) · Urology · doi:10.1016/s0090-4295(02)01686-2 · Cited by 189
Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution
Przybelski, R. J., Daily, E. K., Kisicki, J. C., Mattia‐Goldberg, C., Bounds, M. J., & Colburn, W. A. (1996) · Critical Care Medicine · doi:10.1097/00003246-199612000-00011 · Cited by 138
Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene
Motoyama, N., Okada, N., Yamashina, M., & Okada, H. (1992) · European Journal of Immunology · doi:10.1002/eji.1830221029 · Cited by 108
Complement-specific antibodies: Designing novel anti-inflammatories
Matis, L. A., & Rollins, S. A. (1995) · Nature Medicine · doi:10.1038/nm0895-839 · Cited by 80
Self-citationColnot, D. R., Roos, J. C., de Bree, R., Wilhelm, A. J., Kummer, J. A., Hanft, G., Heider, K., Stehle, G., Snow, G. B., & van Dongen, G. A. M. S. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0396-5 · Cited by 72
Holguin, M. H., Martin, C. B., Bernshaw, N. J., et al. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.2.498 · Cited by 65
Morgan, B. P. (1992) · Biochemical Journal · doi:10.1042/bj2820409 · Cited by 50
Yonemura, Y., Kawakita, M., Koito, A., Kawaguchi, T., Nakakuma, H., Kagimoto, T., Shichishima, T., Terasawa, T., Akagaki, Y., Inai, S., et al. (1990) · British Journal of Haematology · doi:10.1111/j.1365-2141.1990.tb02546.x · Cited by 33
Okada, N., HARADA, R., & OKADA, H. (1990) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1990.tb06449.x · Cited by 26
Cited by
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Rother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Self-citationThe Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P., Young, N. S., Schubert, J., Brodsky, R. A., Socié, G., Muus, P., Röth, A., Szer, J., Elebute, M. O., Nakamura, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061648 · Cited by 1,303
Self-citationDiagnosis and management of paroxysmal nocturnal hemoglobinuria
Parker, C. (2005) · Blood · doi:10.1182/blood-2005-04-1717 · Cited by 783
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778
Metadata
- Authors
- Hillmen, P., Hall, C., Marsh, J. C. W., Elebute, M., Bombara, M. P., Petro, B. E., Cullen, M. J., Richards, S. J., Rollins, S. A., Mojcik, C. F., & Rother, R. P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-02-05
- Volume
- 350
- Issue
- 6
- Pages
- 552-559
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152757679
- Cited by
- 635
- References
- 22
- FWCI
- 10.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.